Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN)

Historical Holders from Q2 2023 to Q3 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
VTGN on Nasdaq
Shares outstanding
31,887,528
Price per share
$3.55
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
23,364,193
Holdings value
$81,815,600
% of all portfolios
0%
Share change
+8,489,380
Value change
+$30,638,554
Average buys %
+0%
Average sells %
-0%
Number of holders
58
Price from insider filings
$0.5626
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 14% $13,205,481 4,165,767 JANUS HENDERSON GROUP PLC 29 Aug 2025
Nantahala Capital Management, LLC 10% 0% $11,130,679 +$1,227,226 3,185,564 +12% Nantahala Capital Management, LLC 30 Sep 2025
BIOTECHNOLOGY VALUE FUND L P 10% $6,353,707 3,084,324 BVF PARTNERS L P/IL 31 Dec 2024
STEMPOINT CAPITAL LP 8.2% $4,796,694 2,328,492 StemPoint Capital LP 31 Dec 2024
GREAT POINT PARTNERS LLC 6.3% -4.4% $7,183,290 2,055,834 0% Great Point Partners, LLC 30 Sep 2025
VANGUARD GROUP INC 5.5% $5,799,733 1,687,735 The Vanguard Group 30 Sep 2025
ORBIMED ADVISORS LLC 5.3% $5,729,276 1,639,700 ORBIMED CAPITAL LLC 30 Sep 2025
As of 30 Sep 2025, Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) has 58 institutional shareholders filing 13F forms. They hold 23,364,193 shares of 31,887,528 outstanding shares (73%) .

Top 25 institutional shareholders own 71% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
JANUS HENDERSON GROUP PLC 13% 4,165,767 0.01% $14,746,815
ORBIMED ADVISORS LLC 9.6% 3,060,000 0.26% $10,863,000
TCG Crossover Management, LLC 8.4% 2,676,580 0% 0.47% $9,501,859
STEMPOINT CAPITAL LP 7.8% 2,488,685 +39% 1.6% $7,749,263
Nantahala Capital Management, LLC 6.2% 1,978,492 0% 0.43% $7,023,647
VANGUARD GROUP INC 5.3% 1,687,735 -4.1% 0% $5,991,460
Commodore Capital LP 4.9% 1,575,000 0% 0.27% $5,591,250
Ikarian Capital, LLC 1.9% 620,869 +3.2% 0.5% $2,204,084
Soleus Capital Management, L.P. 1.7% 550,000 0.1% $1,952,500
BlackRock, Inc. 1.3% 423,128 +1.5% 0% $1,502,105
RENAISSANCE TECHNOLOGIES LLC 1.3% 422,012 +942% 0% $1,498,143
DIADEMA PARTNERS LP 1.1% 349,789 -13% 0.86% $1,241,751
JANE STREET GROUP, LLC 0.95% 302,683 +218% 0% $1,074,525
GEODE CAPITAL MANAGEMENT, LLC 0.94% 298,280 +9.3% 0% $1,059,256
TWO SIGMA INVESTMENTS, LP 0.91% 289,409 +224% 0% $1,027,402
JPMORGAN CHASE & CO 0.85% 271,825 -64% 0% $964,979
Almitas Capital LLC 0.82% 261,399 0% 0.21% $927,966
AdvisorShares Investments LLC 0.65% 206,998 +1.9% 0.12% $734,843
BOOTHBAY FUND MANAGEMENT, LLC 0.62% 197,024 +11% 0.02% $699,435
TWO SIGMA ADVISERS, LP 0.49% 157,032 +508% 0% $557,464
BML Capital Management, LLC 0.47% 150,000 0% 0.49% $532,500
CITADEL ADVISORS LLC 0.38% 122,062 0% $433,320
ADAR1 Capital Management, LLC 0.35% 113,062 -73% 0.04% $401,370
STATE STREET CORP 0.3% 96,858 0% 0% $343,846
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.27% 85,594 -26% 0% $303,859

Institutional Holders of Vistagen Therapeutics, Inc. - Common Stock, par value $0.001 per share (VTGN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 23,364,193 $81,815,600 +$30,638,554 $3.55 58
2025 Q2 14,875,235 $29,750,933 -$917,939 $2.00 50
2025 Q1 15,325,061 $38,287,272 +$856,837 $2.50 47
2024 Q4 14,903,856 $43,958,426 -$1,103,423 $2.95 54
2024 Q3 14,643,797 $44,079,533 +$4,636,496 $3.01 47
2024 Q2 13,044,677 $45,399,902 -$5,789,215 $3.48 42
2024 Q1 14,613,555 $76,690,483 -$1,507,857 $5.28 41
2023 Q4 14,894,924 $76,148,127 +$50,529,562 $5.14 44
2023 Q3 3,003,814 $15,739,243 +$10,118,087 $5.24 34
2023 Q2 965,701 $1,806,003 +$1,806,005 $1.87 28